Table 2.
Self-reported uptake of praziquantel at baseline and follow-up surveys
|
School (no) |
Baseline (N = 1,010) |
Follow-up (N = 1,020) |
P value |
||||
|---|---|---|---|---|---|---|---|
| n | Uptake | % uptake (95% CI) | n | Uptake | % uptake (95% CI) | ||
| 1 |
70 |
12 |
17.1 (2.08–48.4) |
75 |
44 |
58.7 (43.2–73.7) |
0.011 |
| 2 |
61 |
16 |
26.2 (7.27–52.3) |
70 |
39 |
55.7 (39.6–72.2) |
0.047 |
| 3 |
75 |
19 |
25.3 (9.14–51.2) |
70 |
44 |
62.9 (47.8–77.6) |
0.006 |
| 4 |
55 |
38 |
69.0 (51.3–82.4) |
71 |
28 |
39.4 (21.5–59.4) |
0.017 |
| 5 |
31 |
20 |
64.5 (40.7–84.6) |
73 |
30 |
41.4 (22.6–59.4) |
0.109 |
| 6 |
104 |
26 |
25.0 (11.5–47.8) |
100 |
45 |
45.0 (29.6–60.0) |
0.093 |
| 7 |
107 |
25 |
23.4 (9.35–45.1) |
100 |
53 |
53.0 (38.6–66.7) |
0.014 |
| 8 |
107 |
12 |
11.2 (0.21–38.4) |
92 |
56 |
60.9 (46.7–73.5) |
0.002 |
| 9 |
82 |
48 |
58.5 (43.2–72.4) |
71 |
42 |
59.2 (43.2–74.4) |
0.946 |
| 10 |
104 |
17 |
16.3 (3.70–43.4) |
101 |
55 |
54.5 (40.5–68.0) |
0.006 |
| 11 |
110 |
28 |
25.5 (10.6–44.9) |
98 |
13 |
13.3 (1.90–45.4) |
0.377 |
| 12 |
104 |
24 |
23.1 (9.77–46.7) |
99 |
50 |
50.5 (35.5–64.5) |
0.025 |
| Total | 1,010 | 285 | 28.2 (22.9–33.6) | 1,020 | 499 | 48.9 (44.4–53.4) | <0.001 |